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1. Introduction 
Genome-wide association studies (GWAS) have been fruitful in identifying common 
variants underlying many complex human diseases (McCarthy et al., 2008; Altshuler et al., 
2008), with notable success especially in several autoimmune diseases (Lettre & Rioux 2008; 
Zhernakova et al., 2009). Hundreds of distinct genomic loci have been associated with 
various autoimmune diseases, including celiac disease (CeD), Crohn’s disease (CD), 
ulcerative colitis (UC), multiple sclerosis (MS), rheumatoid arthritis (RA), systemic lupus 
erythematosus (SLE) and type 1 diabetes (T1D). Besides individual studies, recent meta-
analysis of GWAS has also enabled the identification of dozens of susceptibility loci for T1D 
(Cooper et al., 2008; Barrett et al., 2009; Bradfield et al., 2011), CD (Barrett et al., 2009; Franke 
et al., 2010), and UC (McGovern et al., 2010; Anderson et al., 2011), since single studies are 
typically underpowered. Additionally, comparisons of susceptibility loci between different 
autoimmune diseases have revealed important insights into their common genetic 
architecture. For example, interleukin 23 receptor (IL23R) has been consistently implicated 
in multiple related autoimmune disorders including CD, UC, ankylosing spondylitis and 
psoriasis, suggesting that it may be a common susceptibility factor for the major 
seronegative diseases (Cargill et al., 2007; Duerr et al., 2006; Tremelling et al., 2007). Another 
study compared shared genetic risk factors for T1D and CeD and reported multiple identical 
risk alleles (Smyth et al., 2008), suggesting that common biologic mechanisms may be 
etiologic features of both diseases. Several similar studies that examined known CD 
susceptibility loci in GWAS for UC identified previously unreported susceptibility loci 
shared by these related disorders (Franke et al., 2008; Anderson et al., 2009; Anderson et al., 
2011). Taken together, these studies suggest that examination of related autoimmune 
diseases can help reveal shared genetic pathways, and that evaluation of known 
susceptibility loci for one disease in GWAS for another disease may uncover novel disease-
loci relationships. The GWAS approach has been made possible by the development of 
high-density genotyping arrays that leverage the knowledge generated from The 
International HapMap project (The International HapMap Project, 2003; International 
HapMap Consortium, 2005). As a consequence, it has been shown that the genome is laid 
out in discrete linkage disequilibrium (LD) blocks with limited haplotype diversity within 
each of these blocks. Therefore, a minimal set of SNPs can detect almost all common 
haplotypes present, thus improving genotyping accuracy and reducing cost. Genome-wide 
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genotyping with in excess of 500,000 SNPs can now be readily achieved to accurately tag the 
vast majority of the diversity in the genome (Steemers et al., 2006; Gunderson et al., 2005; 
Reich et al., 2005). GWAS has been enormously successful through large-scale studies of 
cohorts of patients and controls, providing compelling evidences for genetic variants 
involved in complex autoimmune diseases. A full catalog of these studies is now available at 
the NIH website: http://www.genome.gov/gwastudies (Hindorff et al., 2010).  We are now 
in a rapid phase of data accumulation for many complex disorders, especially T1D and IBD. 
57 loci have now been uncovered to date as being robustly associated with pathogenesis of 
T1D. The chronic IBDs have seen a great success as well. To date there are 99 IBD 
susceptibility loci: 71 associated with CD, 47 with UC, and 28 with both UC and CD.  
In this review, we first provide a summary of these recent discoveries and then discuss the 
shared susceptibility loci implicated in T1D, UC and CD. Our study helps understanding 
the genetic architecture, including shared genetic pathways and risk factors with opposing 
effects for these related diseases. Data were obtained from two main sources: the National 
Human Genome Research Institute catalogue of published genome-wide association studies 
(http://www.genome.gov/gwastudies/; last accessed on 1 April 2011); and PubMed 
literature search. 
2.1 Type 1 diabetes (T1D) 
T1D results from autoimmune destruction of pancreatic beta cells, resulting in a lack of 
insulin production. Of all cases of diabetes, T1D represents approximately 10% and is most 
prevalent in populations of European ancestry, where there is ample evidence of increased 
annual incidence during the past five decades (Onkamo et al., 1999; EURODIAB ACE Study 
Group, 2000). T1D risk is strongly influenced by multiple genetic loci and poorly 
understood environmental factors.  
2.1.1 A genetic component to type 1 diabetes  
T1D is a complex trait that results from the interplay between environmental and genetic 
factors. Many evidences support a strong genetic component associated to T1D. The 
epidemiological data for geographic prevalence differences is one clear indicator, with 
populations of European ancestry having the highest presentation rate. T1D has high 
concordance among monozygotic twins (33 to 42%) (Redondo et al., 2001) and runs strongly 
in families, with the sibling risk being approximately 10 times greater than the general 
population (Clayton, 2009); this is in clear contrast to the “less genetic” type 2 diabetes 
(T2D), where the sibling risk ratio is relatively modest at 3.5 (Rich, 1990).  
2.1.2 Before GWAS 
Historically, prior to GWAS, only five loci have been fully established to be associated with 
T1D. It has been long established that approximately half of the genetic risk for T1D is 
conferred by the genomic region harboring the HLA class II genes (primarily HLA-DRB1, -
DQA1 and -DQB1 genes), which encode the highly polymorphic antigen-presenting 
proteins. Recent fine mapping efforts of the MHC addressed why the class II genes HLA-
DQB1 and HLA-DRB1 cannot completely explain the association between T1D and the 
MHC region (Nejentsev et al., 2007). It turned out that most of the remaining association 
that could be detected was due to signals in HLA-B and HLA-A, and that the existence of 
other major T1D genes in the extended MHC was unlikely. Other established loci prior to 
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GWAS are the genes encoding insulin  (INS) (Bell et al., 1984; Bennett et al., 1995), cytotoxic 
T-lymphocyte-associated protein 4 (CTLA4) (Nistico et al., 1996; Anjos et al., 2004); protein 
tyrosine phosphatase, non-receptor type 22 (PTPN22) gene (Bottini et al., 2004; Smyth et al., 
2004) and interleukin 2 receptor alpha (IL2RA) (Vella et al., 2005; Lowe et al., 2007). 
However, the majority of other reported associations in the pre-GWAS era have remained 
debatable (Guo et al., 2004; Mirel et al., 2002; Biason-Lauber et al., 2005), where an initial 
report of association does not hold up in subsequent replication attempts by other 
investigative groups, known as the “winner’s curse” (Lohmueller et al., 2003).  
2.1.3 GWAS of T1D 
The advent of GWAS has changed the situation dramatically, provided pace and great 
benefit to the discovery of loci associated with T1D, increasing the number of associated 
regions by a factor of ten. An early genome-wide SNP genotyping approach, using only 
6,500 nonsynonymous SNPs (Smyth et al., 2006), represented a precursor to the full GWAS 
approached soon after; however it did uncover a robust association to the interferon-
induced with helicase C domain 1 (IFIH1) gene. IFIH1 exerts its influence through the 
apoptosis of virally infected cells in antiviral immune responses, which may in turn support 
the notion that there is a connection between viral infections and the pathogenesis of T1D 
(Knip et al., 2005). Of interest, subsequent re-sequencing revealed additional rarer, higher 
risk conferring variants residing within the exons of this gene (Nejentsev et al., 2009). The 
first full-scale GWAS for T1D came simultaneously from our group (Hakonarson et al., 
2007) and the Wellcome Trust Case-Control Consortium (WTCCC, 2007). In our study we 
examined a large pediatric cohort of European descent using the Illumina HumanHap 550 
BeadChip platform. The design involved 561 cases, 1,143 controls and 467 triads in the 
discovery stage followed by a replication effort in 939 nuclear families. In addition to 
finding the “usual” suspects, including an impressive 392 SNPs capturing the very strong 
association across the MHC, we identified significant association with variation at the 
KIAA0350 gene, which we replicated in an additional cohort. The WTCCC study investigated 
seven common complex diseases including T1D (WTCCC, 2007) by genotyping 2,000 cases 
and 3,000 controls with ~500,000 SNPs using the Affymetrix GeneChip and reported a number 
of novel T1D loci, including KIAA0350 genomic region. They confirmed these findings in a 
replication study in 4,000 cases and 5,000 controls plus nearly 3,000 T1D family trios that were 
reported in a companion paper that came out on the same day (Todd et al., 2007). In a separate 
replication effort we elected to fast-track 24 SNPs at 23 distinct loci that fell just below the bar 
for genome wide significance in our 2007 GWAS and established association to the 12q13 
region, with a combined P-value of 9.13x10-10 (Hakonarson et al., 2008); this was the same locus 
as the one reported by the WTCCC and Todd et al., 2007. The 12q13 region harbors several 
genes, including ERBB3, RAB5B, SUOX, RPS26 and CDK2. Additional laboratory studies are 
needed to identify both the causative variant and the corresponding genes. The clarity of 
signals found in 2007-2009 T1D GWAS highlights the strength and consistency of GWAS 
approach in contrast to traditional candidate gene and family-based studies where the 
consensus amongst geneticist was weak (Lohmueller et al., 2003).  
2.1.4 Meta-analyses of T1D GWAS datasets 
To date, genome wide genotyping has been relatively expensive, and represents a large 
financial investment when leveraging large, well powered case-control cohorts. In order to 
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get the most from such an endeavor, GWAS investigators have chosen to combine datasets 
from different investigative groups in order to carry out meta-analyses. We used this data-
mining approach to determine additional novel loci associated with T1D (Grant et al., 2009) 
conferring increasingly modest risks in the region of 1.1 to 1.2. Through subsequent rounds 
of testing in an independent cohort of nuclear T1D families from Montreal, the Children’s 
Hospital of Philadelphia and the Type 1 Diabetes Genetics Consortium (T1DGC), followed 
by the WTCCC dataset and the Diabetes Control and Complications Trial 
(DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) study cohort, 
we observed convincing association with the genes encoding ubiquitin-associated and SH3 
domain-containing protein A (UBASH3A) and BTB and broad complex-tramtrack-bric-a-
brac (BTB) and cap 'n' collar (CNC) homology 2 (BACH2). In further support of our finding, 
the UBASH3A locus was subsequently implicated in T1D from a large linkage study using 
dense SNP genotyping data generated on affected sib pairs (Concannon et al., 2008). 
A subsequent meta-analysis by Cooper and colleges (Cooper et al., 2008) using T1D datasets 
from the TCCC (Wellcome Trust Case Control Consortium, 2007) and the Genetics of 
Kidneys in Diabetes (GoKinD) study (Mueller et al., 2006; Manolio et al., 2007), confirmed 
association to the previously observed loci of PTPN22, CTLA4, MHC, IL2RA, 12q13, 12q24, 
CLEC16A and PTPN2 but yielded less evidence for the IFIH1 and INS loci without 
reporting new T1D loci reaching the threshold for genome wide significance. The SNPs with 
lowest nominal P-values were taken forward for further genotyping in an additional British 
cohort of approximately 6,000 cases, 7,000 controls and 2,800 families. As a result, the IL2-
IL21 association strengthened further and they found strong evidence for the following loci: 
BACH2 (as we described previously (Grant et al., 2009)), a 10p15 region harboring the 
protein kinase C, theta gene (PRKCQ), a 15q24 region harboring nine genes including 
cathepsin H (CTSH) and a 22q13 region harboring the C1q and tumor necrosis factor related 
protein 6 (C1QTNF6) and somatostatin receptor 3 (SSTR3). Additional studies are required 
to elucidate the culprit genes and their mechanism at the 15q24 and 22q13 loci. 
The meta-analysis reported by Barrett et al., 2009 uncovered in excess of forty loci, including 
18 novel regions plus confirmed a number of loci uncovered through cross-disease 
comparisons (Smyth et al., 2008; Fung et al., 2009; Cooper et al., 2009). This study not only 
involved samples from WTCCC (WTCCC, 2007) and GoKinD study (Mueller et al., 2006) 
but also brought in a further large set of cases, controls and family sets from T1DGC. In 
addition to confirmation for already known loci they also reported association to 1q32.1 
(which harbors the interleukin genes IL10, IL19 and IL20), Glis family zinc finger protein 3 
(GLIS3) (first suggested by us (Grant et al., 2009), CD69 and IL27. These findings were 
further supported by our in silico replication efforts (Qu et al., 2010).  
To identify additional genetic loci for T1D susceptibility, we examined associations in the 
largest meta-analysis to date between the disease and ~2.54 million SNPs in a combined 
cohort of 9,934 cases and 16,956 controls (Bradfield et al., 2011). Targeted follow-up of 53 
SNPs in 1,120 affect trios uncovered three new loci associated with T1D that reached 
genome wide significance. The most significantly associated SNP (rs539514, P = 5.66x10-11) 
resided in an intronic region of the LMO7 (LIM domain only 7) gene on 13q22. The second 
most significantly associated SNP (rs478222, P = 3.50x10-9) resided in an intronic region of 
the EFR3B (protein EFR3 homolog B) gene on 2p23; however the region of linkage 
disequilibrium is approximately 800kb and harbors additional multiple genes, including 
NCOA1, C2orf79, CENPO, ADCY3, DNAJC27, POMC, and DNMT3A. The third most 
significantly associated SNP (rs924043, P = 8.06x10-9) lied in an intergenic region on 6q27, 
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where the region of association is approximately 900kb and harbors multiple genes 
including WDR27, C6orf120, PHF10, TCTE3, C6orf208, LOC154449, DLL1, FAM120B, 
PSMB1, TBP and PCD2. These latest associated regions add to the growing repertoire of 
gene networks predisposing to T1D. Figure 1 summarizes the 57 coli reported to date. 
 
 
Fig. 1. The 57 type-1 diabetes loci described to date: a timeline.  The loci in T1D are 
presented by the year they were first implicated in the disease. Those loci reported just as a 
chromosomal band are for those regions that are either gene deserts or harbor multiple 
genes from which not a single candidate gene has arisen. Green highlights genes common 
for T1D, CD & UC; Red-between T1D & UC; Blue-between T1D & CD. 
2.2 Inflammatory bowel disease 
The two IBD subtypes, Crohn's disease (CD) and ulcerative colitis (UC) collectively referred 
as Inflammatory bowel disease (IBD), common inflammatory disorders with complex 
etiology involving multiple genes and environmental factors, are characterized respectively 
by confluent inflammation of the colonic mucosa (UC) and discontinuous transmural 
intestinal inflammation (CD). IBD is thought to develop as a result of dysregulation of 
immune response to normal gut flora in a genetically susceptible host based on our current 
knowledge of clinical investigations, gene association studies and laboratory experiments. 
IBD impacts large number of people and is becoming more common in the rest of the world 
with adoption of Western lifestyle. The prevalence of CD and UC has increased significantly 
over the last decade with peak age of onset in the second to fourth decades of life (Lashner 
1995). CD and UC are considered related disorders that have some shared and some distinct 
genetic susceptibility loci. IBD being highly heritable has a complex genetic basis as 
suggested by family, twin, and phenotype concordance studies. When compared to general 
population, familial aggregation studies have reported a greater relative risk for developing 
IBD among twins and first-degree relatives of affected individuals. Monozygotic twins 
compared to dizygotic twins have reported substantially higher disease concordance for 
both CD and UC (Thompson et al., 1996; Duerr, 2003; Halme et al., 2006) 
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It had proven difficult before the advent of GWA studies to isolate disease genes that confer 
susceptibility to CD and UC using classical candidate gene and linkage approaches, with 
two notable exceptions. ‘Caspase recruitment domain family, member 15’ (CARD15; also 
known as NOD2), the first and most widely replicated CD susceptibility gene was 
positionally cloned using linkage analysis in 2001 (Hugot et al., 2001; Hampe et al., 2001). 
Linkage studies approach also discovered CD risk haplotype spanning the organic cation 
transporter, SLC22A4, and other genes on chromosome 5q31 (IBD5) (Rioux et al., 2001; 
Peltekova et al., 2004). Due to extensive linkage disequilibrium (LD) in the region, the 
identity of the causative gene and associated variants has been debated (Duerr et al., 2006). 
GWAS have yielded many positive associations within CD and UC and other autoimmune 
diseases. Duerr et al., 2006 reported the first GWA study of IBD and association between CD 
and variants in the interleukin 23 receptor (IL23R) on chromosome 1p31 in ileal CD cases of 
European ancestry.  
Early-onset IBD demonstrates unique characteristics in clinical phenotype, severity, and 
familial clustering. Extensive anatomical involvement at presentation, with early disease 
progression is now clearly established as a feature of both childhoods CD (Vernier-
Massouille et al., 2008) and UC (Van Limbergen et al., 2008a). Recent data suggest that 
stratifying subjects based upon age-of-onset may be effective in identifying genes 
contributing to IBD pathogenesis, and that individuals with early-onset disease may be 
more genetically enriched and thereby compensate for the  relatively smaller pediatric 
cohorts (Kugathasan et al., 2008; Imielinski et al., 2009). Recent meta-analysis of published 
studies is another approach by which several common genetic factors can be identified. A 
handful of meta-analysis for common susceptibility loci between UC and CD have been 
performed most notably for NOD, PTPN22, ATG16L1, and IGRM (Barrett et al., 2008; 
McGovern et al., 2010; Franke et al., 2010; Anderson et al., 2011). GWAS studies to date, 
combining previously reported pediatric and adult onset IBD studies in a large meta-
analysis, have confirmed 99 IBD susceptibility loci: 71 associated with CD, 47 with UC, and 
28 with both UC and CD (Lees et al., 2011). 
2.3 Comparisons between T1D and IBD 
It is becoming apparent that there is cross-talk between genes influencing autoimmune 
diseases. For instance, it has been shown that the first T1D locus we reported, CLEC16A, has 
also yielded association to multiple sclerosis in a GWAS of that disease (De Jager et al., 2009) 
and that PTPN22 has been similarly implicated in Crohn’s disease, rheumatoid arthritis, 
systemic lupus erythematosus and autoimmune thyroiditis (Hafler et al., 2007; Bottini et al., 
2006). In addition, from our earlier comparative genetic analyses of inflammatory bowel 
disease and type 1 diabetes, we have intriguingly implicated multiple loci with opposite 
effects (Wang et al., 2010).  
2.3.1 T1D and IBD (UC and CD) – common genes: IL10, IL2/IL21, ORMDL3, PTPN2, 
CLEC16A 
IL10 (1q32) 
The IL10 gene, located in chromosome 1, encodes Interleukin 10, which is an anti-
inflammatory cytokine produced primarily by monocytes and lymphocytes. IL10 has 
pleiotropic effects in immunoregulation and inflammation. Franke et al., 2008 GWAS first 
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Fig. 2. Venn Diagram of known susceptibility loci that are shared by Crohn’s disease, 
ulcerative colitis and type 1 diabetes. Red represents opposite direction for T1D and IBD: 
protection in one disease versus susceptibility in another.  
with UC. Barrett et al., 2009 meta-analysis study revealed association with T1D. Study from 
our group (Wang et al., 2010) reported IL10 as novel association for CD with alleles having 
opposite direction of association between T1D and IBD (including both UC and CD) and the 
SNP rs3024505 confers protection to UC and CD. Later Franke et al., 2010 meta-analysis 
study of six Crohn’s disease GWAS comprising of 6,333 affected individuals and 15,056 
controls and followed up the top association signals in 15,694 cases, 14,026 controls and 414 
parent-offspring trios confirmed the association.  
IL2/IL21 (4q27) 
The IL2 gene and IL21 gene are located on chromosome 4, encode Interleukin 2 and 
Interleukin 21, respectively. IL2 protein is a secreted cytokine important for the proliferation 
of T and B lymphocytes. IL2 signals through a receptor complex consisting of IL2 specific 
IL2 receptor alpha (CD25), IL2 receptor beta (CD122) and a common gamma chain shared 
by all members of this cytokine family. Binding activates the Ras/MAPK, JAK/Stat and PI 
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3-kinase/Akt signaling modules. Interleukin 21 is a cytokine with potent regulatory effects 
on cells of the immune system, including natural killer (NK) cells and cytotoxic T cells that 
can destroy virally infected or cancerous cells (Parrish-Novak et al., 2002).  
GWAS provides evidences for 4q27 region association with a number of autoimmune 
phenotypes, type 1 diabetes and Graves' disease (GD) (Todd et al., 2007),  systemic lupus 
erythematosus (SLE) (Sawalha et al., 2008), psoriatic arthritis (Liu et al., 2008) and juvenile 
idiopathic arthritis (Albers et al.,), ulcerative colitis (Festen et al., 2009), Crohn's disease 
(Marquez et al., 2009a), and celiac disease (Garner et al., 2009). This region contains four 
genes in strong linkage disequilibrium (LD): KIAA1109-TENR-IL2-IL21. KIAA1109 and 
ADAD1 (adenosine deaminase domain containing 1 protein with testis specific expression) 
genes have no known relationship to immune function, while IL2 and IL21 are both of 
interest, especially because IL2 is a risk gene for T1D in the non-obese diabetic mouse 
(Yamanouchi et al., 2007). The extensive linkage disequilibrium across the region is 
preventing fine-mapping efforts (Todd et al., 2007) suggesting resequencing followed by 
genotyping to identify all the variants with association in KIAA1109-TENR-IL2-IL21 region.   
CLEC16A (16p13) 
The CLEC16A gene, located on chromosome 16, encodes protein with unknown function. 
The exclusive expression specificity of CLEC16A in immune cells including dendritic cells, B 
lymphocytes and natural killer (NK) cells, all of which are pivotal in the pathogenesis of 
T1D (Poirot et al., 2004; Rodacki et al., 2007) indicates that the variant probably contributes 
to the disease by modulating immunity. Hakonarson et al., 2007 performed GWAS in a large 
pediatric cohort of European descent to identify new genetic factors that increase the risk of 
T1D and found that T1D was significantly associated with variation within a 233-kb linkage 
disequilibrium block on chromosome 16p13. Three common non-coding variants of the gene 
(rs2903692, rs725613 and rs17673553) in strong linkage disequilibrium reached genome-wide 
significance for association with T1D. A subsequent replication study in an independent 
cohort confirmed the association. There are no other genes in 16p13 region, making 
CLEC16A (also known as KIAA0350) a prime candidate for harboring the causative variant. 
We investigated the expression of KIAA0350 in four different NK cell lines and found 
higher expression in the NKL cell line; interestingly, this cell line is homozygous for allele A 
of rs2903692. WTCCC 2007 GWAS discovered KIAA0350 as T1D susceptibility locus. 
Several studies later confirmed the association with T1D (Todd et al., 2007; Cooper et al., 
2008), pathogenesis of MS (De Jager et al., 2009) and Celiac disease (Dubois et al., 2010). 
Recent studies of the novel Drosophila gene, ema (endosomal maturation defective), 
orthologue of human CLEC16A, have defined roles for the protein in regulating endosomal 
trafficking (Kim et al., 2010). Such function suggests mechanisms by which CLEC16A may 
confer susceptibility to autoimmune disorders. In 2009, Marquez et al. concordantly with the 
already reported function of this locus in T1D and MS, showed the specific association of a 
CLEC16A/KIAA0350 polymorphism with a distinct group of NOD2-/CARD15 Crohn’s 
disease patients. These new evidence argues in favor of the hypothesis that alterations in 
genetic factors involved in bacterial recognition through different pathways result in CD, 
which may allow more insight into processes critical to the pathogenesis of this IBD.  
ORMDL3 (17p12) 
The ORMDL3 gene, located on chromosome 17, encodes ORM1-like 3 protein of unknown 
function which is expressed heart, brain, lung liver and kidney. Common SNPs in the 
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chromosome 17q12 region reported by GWAS is known to alter the risk for asthma and also 
linked with the expression level of the ORM1-like 3 (ORMDL3) gene (Moffat et al., 2007). 
SNP (rs7216389) was highlighted as the potential causal variant based on evolutionary 
conservation. Several studies have replicated this association for adult asthma in different 
ethnic groups (Sleiman et al., 2008; Madoreet et al., 2008; Galanter et al., 2008; Hirota et al., 
2008). The rs7216389 SNP is found within a large linkage disequilibrium (LD) block that 
encompasses not only ORMDL3, but also gasdermin B (GSDMB), zona pellucida binding 
protein 2 (ZPBP2), and IKAROS family zinc finger 3 (Aiolos) (IKZF3) genes. Another variant 
(rs2872507) located within this same LD block has been associated with CD (Barrett et al., 
2008 GWAS and Franke et al., 2010 meta-analysis), suggesting that the same polymorphism 
confers susceptibility to both CD and asthma. More recently, the same region was associated 
with the risk of type 1 diabetes (for SNP rs2290400) (Barrett et al., 2009) and UC (McGovern 
et al., 2010) for rs2305480. Further elucidation of the genetic mechanisms of transcriptional 
control of the ORMDL3 genomic region may potentially shed light on the pathogenesis of 
multiple complex diseases. 
PTPN2 (18p11) 
The PTPN2 gene, located on chromosome 18, encodes a tyrosine-protein phosphatase 
nonreceptor type 2, a key negative regulator of inflammatory responses is expressed in cells 
of the immune system and islet ȕ-cells. Recent studies point out the possible role of PTPN2 
in preventing ȕ-cell apoptosis (Moore et al., 2009).  
WTCCC 2007 and Barret et al., 2008 identified PTPN2 as CD susceptibility gene. Franke et 
al., 2008 and Dubois et al., 2010 GWAS associated PTPN2 as previously unknown disease 
loci for UC. Hakonarson et al., 2007 and Todd et al., 2007 GWAS, Cooper et al., 2008 and 
Barrett et al., 2009 meta-analysis associated PTPN2 as T1D susceptibility gene. Feston et al., 
2011 meta-analysis identified PTPN2 as shared risk loci for Crohn's disease and celiac 
disease. Of special interest to CD, PTPN2 regulates intestinal epithelial barrier function, thus 
identifying a novel link between disease associated gene and a key patho-physiological 
event in CD (Scharl et al., 2009). SNP rs1893217(C), an autoimmune associated variant in 
PTPN2, reveals an impairment of IL2R signaling in CD4+ T cells (Long et al., 2011). Scharl et 
al., 2011 demonstrated that PTPN2 is activated by TNF-α and regulates TNF-α-induced 
MAPK signaling and on a functional level, loss of PTPN2 is associated with increased 
expression and secretion of proinflammatory mediators in the intestinal epithelium, a 
potential role for PTPN2 in the pathogenesis of CD. 
2.3.2 Type 1 diabetes and Crohn’s disease – common genes: PTPN22, IL18RAP, 
BACH2, TAGAP, IL2RA, IL27, TYK2, MTMR3)  
PTPN22 (1p13)  
The PTPN22 gene, located in chromosome 1, encodes tyrosine-protein phosphatase 
nonreceptor type 22, a lymphoid-specific phosphatase, an important downregulator of T cell 
activation. It is mainly expressed in T cells, B cells, NK cells, macrophages, monocytes, and 
dendritic cells. Initially PTPN22 polymorphism (C1858T) was associated and originally 
described in T1D patients (Bottini et al., 2004). This was consistently replicated in 
independent population’s studies (Smyth et al., 2004; Santiago et al., 2007). Later the same 
polymorphism was associated with several autoimmune disorders, including rheumatoid 
arthritis (Begovich et al., 2004; Orozco et al., 2005), systemic lupus eritematosus (Orozco et 
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al., 2005), Wegener’s granulomatosis (Jagiello et al., 2005) and myasthenia gravis 
(Vandiedonck et al., 2006). C1858T polymorphism is a non-synonymous SNP with a 
substitution of arginine for tryptophan in the encoded protein (R620W). Functional studies in 
mice revealed that LYP (the mouse ortholog of PTPN22) has an increased phosphatase activity 
in presence of 1858T allele. The 620W autoimmune risk allele behaves as a gain-of-function 
mutation and results in a phosphatase with higher catalytic activity and more potent negative 
regulation of T-cell activation (Vang et al., 2005). By contrast, knockout mice have increased T-
cell activation and an increased production of antibodies (Hasegawa et al., 2004).  
PTPN22 was the first and most convincing example of common susceptibility genes 
underlying diverse autoimmune phenotypes. First GWAS for T1D reported PTPN22 as a 
susceptibility locus (Todd et al., 2007; Hakonarson et al., 2007). Later PTPN22 was associated 
with RA (Plenge et al., 2007, Stahl et al., 2010), Crohn’s disease (Barrett et al., 2008), Graves’ 
disease, Hashimoto thyroiditis, myasthenia gravis, systemic sclerosis, generalized vitiligo (Jin 
et al., 2010). For T1D and RA the 620W allele confers almost two-fold risk for the disease, with 
3-4 odds rations for homozygous patients, making PTPN22 second in importance locus (after 
MHC), in terms of association strength, for these two diseases (Gregerson & Olsson, 2009). 
Barrett et al., 2008 was first to report “intriguing contrasts between genetic susceptibility to CD 
and other complex disorders”. They found that the same coding variant (620W) that is a risk 
factor for T1D and RA provides protection from CD. Our group in latest GWAS confirmed 
both the association for T1D and CD as well as protection for CD (Wang et al., 2010). In 
summary, the minor allele of PTPN22 variant 620W predisposes a person to many immune-
mediated diseases but is protective for Crohn’s disease (Barrett et al., 2008; Wang et al., 2010). 
IL18RAP (2q12) 
The IL18RAP gene, located on chromosome 2, encodes Interleukin 18 receptor accessory 
protein. IL18RAP is strongly expressed in unstimulated T cells and NK cells (Su et al., 2004). 
The coexpression of IL18R1 and L18RAP is required for the activation of NF-κB and MAPK8 
(JNK) in response to IL18. 
IL18RAP is a long confirmed locus for type 1 diabetes. Smyth et al., 2008 genotyped DNA 
samples from 8064 T1D patients, 9339 control subjects, and 2828 families for eight loci 
previously known risk loci of celiac disease and reported association of  IL18RAP and 
TAGAP genes with T1D (P<1.00×10-4) and showed that the minor alleles of the SNP 
rs917997-A for IL18RAP gene confers protection in T1D. Zhernakova et al., 2008 
demonstrated strong association of rs917997 SNP for CD. The rs917997 genotype strongly 
correlates with lower IL18RAP expression in individuals homozygous for the risk allele, 
which may lead to differential IL18-mediated innate immune responses to infection 
(Zhernakova et al., 2010). In recent GWAS we confirmed IL18RAP region as T1D and CD 
loci and reported an opposite direction of association for the same allele residing in 
IL18RAP gene (rs917997) for T1D and CD (Wang et al., 2010). Meta-analysis studies by 
Franke et al., 2010 confirmed ones again IL18RAP as CD locus. Festen et al., 2011 meta-
analysis study reported allele rs6708413-G residing in IL18RAP as a shared risk locus for CD 
and Celiac disease, validating previously identified associations.  
BACH2 (6q15) 
The BACH2 gene ‘BTB and CNC homology 1, basic leucine zipper transcription factor 2’, 
located on chromosome 6, encodes a protein which functions as a transcription repressor 
(Oyake et al., 1996). It possesses BTB/POZ domain and bZip domain. Bach2 forms 
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heterodimers with the small Maf proteins (MafK, MafG and MafF) through the leucine 
zipper and then binds to the Maf-recognition elements (MARE). BACH2 is abundantly 
expressed in both B cells and neurons (Hoshino & Igarashi, 2002).  
GWAS provided convincing associations of BACH2 with T1D in unrelated data sets (Grant 
et al., 2009; Cooper et al., 2008; Barrett et al., 2009). A second-generation GWAS of 4,533 
celiac disease cases and 10,750 controls revealed rs10806425-A allele as a risk factor for celiac 
disease (Dubois et al., 2010). Meta analysis confirmed BACH2 as a susceptibility gene for 
both Celiac disease and CD, with rs1847472-G being a common risk allele (Franke et al., 
2010).  
TAGAP (6q25) 
The TAGAP gene, located on chromosome 6, encodes T-cell activation RhoGTPase-
activating protein, associated with multiple autoimmune diseases: T1D, CD, Celiac disease, 
and RA. With less known role in immune function, it has been found to be co-regulated 
with IL2 and is expected to play a role in T cell activation (Mao et al., 2004; Chang & Hsiao, 
2005).  
Smyth et al., 2008 first reported association of TAGAP with T1D (P<1.00×10-4).  Recent 
genotyping study using the Sequenom MassArray platform reported TAGAP (rs182429) as 
an overlapping genetic susceptibility variant between three autoimmune disorders: RA, T1D 
and coeliac disease (Eyre et al., 2010). Franke et al., 2010 meta-analysis reported TAGAP 
association with CD, which was confirmed in another meta-analysis as common allele 
between CD and CelD (Festen et al., 2011). Interestingly, the TAGAP minor allele confers 
protection against RA (Eyre et al., 2010), similar to previous reports of T1D (Smyth et al., 
2008) but contrasting in CD (Franke et al., 2010; Festen et al., 2011) and celiac disease (Smyth 
et al., 2008) in which the minor allele is associated with risk. 
IL2RA (10p15) 
The IL2RA gene, located on chromosome 10, encodes α subunit of the IL2 receptor complex, 
thus mediating IL2 signaling in host defense and regulating response to autoantigens by 
Tregs. The imbalance between Th1 and Th2 cytokines plays a crucial role in the regulation of 
the immune response and in the pathogenesis of autoimmune diseases (Cantagrel et al., 
1999; Sartor, 1994). Thus, the genes encoding Th1 and Th2 cytokines and their receptors 
might be considered good candidates to modify the risk of these diseases.  
IL2RA was associated with T1D even before advent of GWAS (Vella et al., 2005). Several 
GWAS consistently confirmed the association with (WTCCC 2007; Cooper et al., 2008; 
Barrett et al., 2009). IL2RA was also implicated in MS (Hafler et al., 2007; De Jager et al., 
2009), RA (Stahl et al., 2010). Most recently meta-analysis confirmed the association with 
Crohn's disease (Franke et al., 2010).  
ZFP36L1 (14q24) 
14q24 is common susceptibility locus shared between T1D and CD. Barrett at al., 2009 meta-
analysis first reported rs1465788-G (14q24.1) to be a risk allele for type 1 diabetes; with two 
genes to be present at this LD region: C14orf181 and ZFP36L1. rs4899260-A in region 
14q24.1 was found in GWAS to be a risk allele for Celiac (Dubois et al., 2010). Meta-analysis 
study associated rs4902642-G in the same region as a risk allele for CD (Franke et al., 2010).  
The region contains C14orf181 and ZFP36L1 gene. ZFP36L1 gene is a functionally 
interesting candidate located on chromosome 14, encodes Zinc finger protein 36 C3H type-
like 1, a modulator of mRNA stability.  
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IL27 (16p11) 
The IL27 gene, located on chromosome 16, encodes Interleukin 27, a cytokine secreted by 
stimulated antigen-presenting cells. IL27 is a member of the same family as IL12 and IL23. 
Initially it was associated only with the differentiation of TH1 lymphocytes, enhancement of 
the cellular type immune response, and the reciprocal inhibition of TH2 humoral immune 
reactions (Lucas et al., 2003). Later it was shown to play an important role in regulating the 
activity of B & T lymphocytes as well as NK cells (Larousserie et al., 2006). It could be 
important to pathogenesis of autoimmune diseases, that IL27 promotes cell-mediated 
immune reactions and limits inflammatory reactions (Jankowski et al., 2010). GWAS 
revealed association of IL27 with T1D (Barrett et al., 2009) and early onset IBD (Imielinski et 
al., 2009). In recent GWAS we confirmed IL27 (SNP rs4788084) as T1D locus and reported a 
new association with Crohn’s disease. We also showed that T1D risk allele residing at the 
IL27 loci protects against CD (Wang et al., 2010). Recent meta-analysis of six CD GWAS 
confirmed IL27 as susceptibility locus for CD (Franke et al., 2010). 
TYK2 (19p13) 
The TYK2 gene, located on chromosome 19, encodes tyrosine kinase 2, a member of the JAK-
signal transduction family. It is involved in cytokine signaling by IFN-Ȗ, IL12 and IL23 and 
affects Th1 and Th17 lineage development. TYK2 also plays an important role in TLR-
mediated responses in dendritic cells, including IL12 and IL23 production, and TYK2 
mutations predispose to opportunistic infection (Ghoreschi et al., 2009). Initially, TYK2 gene 
has been associated with SLE (Suarez-Gestal et al., 2009) and MS (Mero et al., 2010). Only 
meta-analysis provided enough power to support at genome-wide significance for TYK2 
associations with T1D (Wallace et al., 2010) and CD (Franke et al., 2010). 
2.3.3 Type 1 diabetes and ulcerative colitis – common genes: TNFAIP3, IL26, HERC2 
TNFAIP3 (6q23) 
The TNFAIP3 gene, located on chromosome 6, encodes tumor necrosis factor, alpha-induced 
protein 3. This protein is a key regulator of NF-κB signaling pathway, modulates cell 
activation, cytokine signaling and apoptosis (Beyaert et al., 2000). The first association 
between autoimmune disease and SNPs spanning TNFAIP3 was identified for RA (Plenge 
et al., 2007). Then TNFAIP3 region was reported as a novel susceptibility locus for SLE 
(Graham et al., 2008) in Europeans and later it was confirmed in Asian populations (Han et 
al., 2009; Shimane et al., 2010). Fung et al., 2009 GWAS reported an association with T1D for 
two statistically independent SNPs rs6920220 and rs1049919. More recently, we tested this 
T1D loci susceptibility (TNFAIP3) in GWAS and discovered that it confers UC risk (Wang et 
al., 2010). Dubois et al., 2010 in GWAS reported association with celiac disease. Anderson et 
al., 2011 meta-analysis confirmed the association of TNFAIP3 as UC risk loci. 
IL26 (12q15) 
The IL26 (Interleukin 26) gene is located on chromosome 12 between the genes for two other 
important class 2 cytokines, IFN-Ȗ and IL22 (Wilson et al., 2007). IL26 is a 171-amino acid 
protein and shares sequence homology to interleukin 10. IL26 signals through a receptor 
complex comprising two distinct proteins called IL20 receptor 1 and IL10 receptor 2 (Sheikh 
et al., 2004). First time, rs2870946-G and rs1558744-A in region 12q15 were associated with 
UC (Silverberg et al., 2009). Meta-analysis study further confirmed the association of 
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rs1558744-A with UC (McGovern et al., 2010). Later GWAS from our group reported new 
association of rs1558744 variant with T1D (Wang et al., 2010).  
HERC2 (15q13) 
The HERC2 gene, located on chromosome 15, encodes a novel ubiquitin ligase required 
for DSB-associated histone ubiquitylation. This gene belongs to the HERC gene family 
that encodes a group of unusually large proteins with multiple structural domains. The 
protein has a COOH-terminal HECT domain, a motif responsible for E3 ubiquitin ligase 
activity. It was recently shown that HERC2 is implicated in DNA damage repair functions 
(Bekker-Jensen et al., 2010). At first in a GWAS, rs916977 variant in HERC2 was identified 
and confirmed as susceptibility loci specific to ulcerative colitis (Franke et al., 2008). 
GWAS from our group later identified rs916977 variant as novel association with T1D 
(Wang et al., 2010).  
2.3.4 Crohn’s disease and Ulcerative colitis – 32 common loci 
IL23R (1p31) 
The interleukin-23 receptor (IL23R) gene is located on chromosome 1p31 encodes receptor 
protein for IL23. IL23R is highly expressed in dendritic cells. This protein associates 
constitutively with JAK2, and also binds to transcription activator STAT3 in a ligand-
dependent manner. Duerr et al., 2006 GWAS first identified the IL23R gene as a CD 
susceptibility gene in North American population, which indicated that the rare IL23R SNP 
rs11209026 (p.Arg381Gln; c.1142G>A) was associated with strong protection against CD. 
Since then this association has been replicated in both CD (Umeno et al., 2011; Ferguson et 
al., 2010) and UC (Umeno et al., 2011; Anderson et al., 2011; WatermanM et al., 2010), and 
also in pediatric CD (Baldassano et al., 2007; Gazouli M et al., 2010), psoriasis (Bowes & 
Barton, 2010), and ankylosing spondylitis (Laukens et al., 2010) by several GWAS and meta-
analysis studies. Of importance, is notably the presence of multiple associations within the 
IL23R gene to CD and UC to date, suggests rigorous involvement of IL-23 pathway in IBD 
pathogenesis. These broad range associations might be attributed to the effect of different 
causal variants on different haplotypes or biological differences in the function of IL-23 and 
IL-23R signaling in different diseases. Additional genetic, bioinformatic, and laboratory 
assessments of association signals supplemented by deep resequencing efforts are needed to 
define more clearly susceptibility genes and contributing susceptibility alleles, especially 
where the association signals span several candidate genes to identify rare variants 
contributing to IBD pathophysiology.  
KIF21B (1q32) 
KIF21B gene, located on chromosome 1 encodes for Kinesin member 21B protein. Kinesin 
family proteins are microtubule-dependent molecular motors involved in the intracellular 
motile process and organelle transport. KIF21B expression is detected in lungs, brain, testes 
and thymus (Harada et al., 2007). In the immune system, expression is highest in CD4+ and 
CD8+ T cells, CD56bright NK cells and B cells (T1Dbase, http:// www.t1dbase.org/). Of 
importance, the mouse homologue, Kif21b, is located in a region linked to susceptibility 
(Idd5.4a) for a mouse model for diabetes (Hunter et al., 2007). SNP rs11584383, located 
downstream of KIF21B was one among the 21 novel loci reported to be associated with CD 
in GWAS by Barrett et al., 2008. Several GWAS  later identified KIF21B as ulcerative colitis 
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susceptibility loci (Franke et al., 2008; Anderson et al., 2009; McGovern et al., 2010). Recent 
meta-analysis studies have confirmed and reported it as common susceptibility loci between 
CD and UC (Anderson et al., 2011 and Umeno et al., 2011). 
TNFRSF9, ERFFI1, UTS2, PARK7 (1p36) 
The region 1p36 recently shown to be associated with IBD contains several genes. Tumor 
necrosis factor receptor superfamily, member 9 (TNFRSF9), contributes to the clonal 
expansion, survival, and development of T cells. ERBB receptor feedback inhibitor 1 
(ERFFI1) is negative regulator for several RGFR family members. Urotensin 2 (UTS) is a 
potent vasoconstrictive peptide that regulates both endothelium-dependent and 
independent vasodilation. Parkinson disease autosomal recessive early onset 7 (PARK7) is 
positive regulator of androgen receptor-dependent transcription. Dubois et al., 2010 
GWAS reported association of TNFRSF9 and PARK 7 with UC in European population. 
Anderson et al., 2011 meta-analysis further confirmed the reported association of 1p36.23 
region with UC. 
PUS10 (2p16) 
PUS10 gene, located on chromosome 2, encodes ‘pseudouridylate synthase 10’ which 
catalyzes pseudouridination of universally conserved Psi55 in tRNA. These enzymes act as 
RNA chaperones, facilitating the correct folding and assembly of tRNAs (McCleverty et al., 
2007). Barrett et al., 2008 was first to report PUS10 as susceptibility loci for Crohn’s disease 
through GWAS. Meta-analysis study identified as a risk locus in UC (McGovern et al., 2010) 
and CelD (Dubois et al., 2010) indicating that this locus is a shared risk locus. Recently 
Festen et al., in 2011, through a meta-analysis of GWAS data from CD and CeID as a single 
disease phenotype established PUS10, as shared risk loci of genome-wide significance, with 
p-value of 1.38X10-11 along-with IL18RAP, PTPN2 and TAGAP, as shared risk loci for 
Crohn’s Disease and Celiac Disease. This meta-analysis approach provided the power, 
lacking in individual disease-specific GWAS datasets, to identify shared risk loci with small 
effects in each single disease. 
REL (2p16) 
The REL gene located on chromosome 2, encodes c-Rel, a transcription factor that is a 
member of the Rel/NFKB family, which also includes RELA, RELB, NF-κB1/p50, and NF-
κB2/p52. All five NF-kB members share a highly conserved 300 amino acid long N-terminal 
Rel homology domain (RHD), responsible for DNA binding, dimerization, nuclear 
localization, and binding to the NFKB inhibitor. REL plays a critical role through the 
production of pro-inflammatory cytokines and coordinating the expression of genes that 
control immune response, anti-apoptotic molecules and cell cycle modulators (Chen et al., 
2003; Hayden et al., 2006; Belguise & Sonenshein, 2007; Tian & Liou 2009). Several studies 
have reported the effect of c-Rel in relation to autoimmune diseases, ESL (Burgos et al., 
2000) and IBD (Neurath et al., 1998, Visekruna et al., 2006). The REL locus is common to UC, 
CD and RA. Zhernakova et al., 2008 reported moderate association of REL polymorphisms 
to UC. In 2009 Trynka et al., discovered two new loci, REL and OLIG3/TNFAIP3 to be 
associated to coeliac disease. Gregersen et al., 2009 described the association of the intronic 
single nucleotide polymorphism (SNP) rs13031237G→T in the REL gene as a risk factor for 
RA in an expansion of previous genome-wide association studies. Varade et al., 2011 
reported first association of REL gene polymorphism in SLE. Recent GWAS studies reported 
epistasis between CARD9 and Rel in ulcerative colitis (McGovern et al., 2010) and Crohn’s 
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disease (Dubois et al., 2010). Franke et al., 2010 meta-analysis further established the Rel 
association, increasing the number of CD susceptibility loci to 71. 
GCKR (2q23) 
GCKR gene located on chromosome 2 encodes, glucokinase (hexokinase 4) regulatory 
protein belonging to the GCKR subfamily. GCKR is implicated in metabolic traits such as 
triglyceride (Aulchenko et al., 2009), fasting glucose (Dupuis et al., 2010) and serum uric 
acid (Kolz et al., 2009). Franke et al., 2010 meta-analysis first reported the association of 
GCKR as Crohn's disease susceptibility loci. Meta analysis study published by Umeno et al., 
2011 confirmed the association of GCKR never had been shown associated with UC in any 
single studies performed to date. However, there is little information how this gene affects 
the development of CD and UC. Functional analysis will provide further understanding of 
the common pathogenesis of CD and UC. 
ATG16L1 (2q37) 
ATG16L1 gene, located on chromosome 2, encodes the autophagy-related 16-like 1 protein 
involved in the formation of autophagosomes during autophagy. Hampe et al., 2007 GWAS 
first identified ATG16L1 as a susceptibility gene for CD and demonstrated the expression of 
mRNA and protein in the colon, small intestine, intestinal epithelial cells and leukocytes 
with no difference in protein expression in intestinal tissues between CD and healthy 
controls. In constrast, Lees et al., 2008 demonstrated down-regulated ATG16L1 mRNA in 
colonic CD biopsies compared with healthy controls in microarray dataset. Analysis further 
confirmed the marker, rs2241880, was an SNP that encodes a threonine to alanine 
substitution (T300A) at amino acid position 300 which was correlated with the incidence of 
CD in two German and one British studies  (Rioux et al., 2007). Prescott et al., 2007 reported 
a non-synonymous SNP in ATG16L1 predisposes to ileal Crohn's disease independent of 
CARD15 and IBD5. Roberts et al., 2007 reported strong association of IL23R, R381Q and 
ATG16L1 T300A with CD in a study of New Zealand Caucasians with IBD. Glas et al., 2008 
reported strong association of ATG16L1 gene variants rs2241879 and rs2241880 (T300A) to 
CD in German population. Weersma et al., 2009 confirmed the genetic association of 
ATG16L1 along-with multiple CD susceptibility loci in a large Dutch-Belgian cohort. In 
addition, a number of studies included child-onset IBD cases, the results of which were also 
confusing and conflicting. Baldassano et al., 2007 reported association of the T300A non-
synonymous variant of the ATG16L1 gene with susceptibility to pediatric Crohn's disease. 
Subsequently Van Limbergen et al., 2008b, reported ATG16L1 gene influences susceptibility 
and disease location but not childhood onset in Crohn's disease in Northern Europe 
population. The study by Latiano et al., 2008 confirmed the association ATG16L1 with CD, 
in both adult and pediatric-onset subsets. A meta-analysis in Spanish population by 
Marquez et al., 2009a reported Thr300Ala polymorphism association with CD, regardless of 
the CARD15 or IL23R status, but not with UC. The meta-analysis by Cheng et al., 2010 
reported ATG16L1 T300A polymorphism with susceptibility to both CD and UC. Recent 
study by Platinga et al., 2011 demonstrates that the genetic variant of human ATG16L1, 
which confers a higher risk for CD is associated with elevated production of pro-
inflammatory cytokines after engagement of NOD2, thereby provide an explanation for the 
excessive inflammatory response observed in CD caused by microorganisms that reside in 
the gut. These findings implicate the role of autophagy and intestinal microbes in the 
pathogenesis of IBD, and demonstrate the need for further studies. 
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MST1, UBA7, APEH, AMIGO3, GMPPB, BSN (3p21) 
Raelson et al., 2007 GWAS first reported association of 3p21 SNP rs11718165 with CD. 
GWAS undertaken by the WTCCC 2007 reported different SNP rs9858542 associated with 
CD in Spanish population. Several studies have reported association with UC also (Fisher et 
al., 2008, Franke et al., 2008, & Anderson et al., 2011 meta-analysis). Marquez et al., 2009c 
reported two SNPs significantly associated with CD. Beckly et al., 2008 demonstrated strong 
epistasis with known CD associated variants in CARD15. Latiano et al., 2010 confirmed the 
association of variants (BSN and MST1) at the 3p21 locus influence susceptibility and 
phenotype both in adults and early-onset patients with IBD. Morgan et al., 2010 replicated 
the reported association in the 3p21 region with CD in New Zealand population. Meta-
analysis by Umeno et al., 2011 confirmed the association of BSN-MST as common 
susceptibility loci between UC and CD.  Designated as IBD9, 3p21 potentially is an 
important IBD locus, previously identified by early genome-wide linkage and fine mapping 
studies. This region contains CD candidate genes like MST1, UBA7, APEH, AMIGO3, 
GMPPB, and BSN. MST1, macrophage stimulatory protein 1, is involved in inflammation 
and tissue remodeling for wound healing. Goyette et al., 2008 first identified a non-
synonymous coding variant (rs3197999, R689C) in MST1 gene associated with both CD and 
UC. APEH encodes a serine peptidase with a functional role in the degradation of bacterial 
peptide break down products in the gut to prevent excessive immune response. 
Amphoterin-Induced Gene and ORF 3 (AMIGO3), member of the AMIGO family of type I 
transmembrane proteins are thought to play roles in neuronal axon tract development and 
cell adhesion. Ubiquitin-like modifier-activating enzyme 7 protein in humans is encoded by 
the UBA7 gene. GPX1 encodes the antioxidant, glutathione peroxidase isoform 1. The BSN 
(bassoon) gene encodes a protein known neurotransmitter released at central nervous 
system synapses. Recent GWAS have provided evidence for the involvement of 3p21 in the 
pathogenesis of IBD, although it remains unclear which is the causative SNP and/or gene. 
PTGER4 (5p13) 
Prostaglandin E receptor 4 protein encoded by PTGER4 gene located on chromosome 5 
belongs to the G-protein coupled receptor family and is one of four receptors identified for 
prostaglandin E2 (PGE2) that can activate T-cell factor signaling, mediates PGE2 induced 
expression of early growth response 1 (EGR1), regulates the level and stability of 
cyclooxygenase-2 mRNA, and lead to the phosphorylation of glycogen synthase kinase-3. 
Libioulle et al., 2007 first described the localization of PTGER4 as novel major susceptibility 
locus for CD to gene desert on 5p13.1 by GWA in Belgian cohort. Kurz et al., 2006 
previously reported PTGER4 as asthma susceptibility loci through fine mapping and 
positional candidate studies on chromosome 5p13. PTGER4 is a strong candidate 
susceptibility gene for CD as PTGER4 knock-out mice have increased susceptibility to 
dextran sodium induced colitis (Kabashima et al., 2002), further supported by the 
observation that the CD susceptibility allele at marker rs4495224 was associated with 
increased PTGER4 transcript levels in lymphoblastoid cell lines.  The association of PTGER4 
as susceptibility loci for Crohn's disease was further replicated through independent GWAS 
(Barrett et al., 2008; Franke et al., 2010).  
SLC22A4/SLC22A5/IRF1/IL3 (5q31)  
The candidate genes encompassed at locus 5q31.1 includes a cytokine gene cluster (IL5, IL4, 
IL13), interferon regulator factor 1(IRF1), SLC22A4 (solute carrier family 22 member 4) and 
SLC22A5 (solute carrier family 22 member 5). SLC22A5 and SLC22A4 are high affinity 
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sodium-dependent uptake transporters that function in the transport of L-carnitine and 
elimination of cationic drugs in the intestine. The locus 5q31 known as IBD5 was first 
associated with CD in genome-wide linkage scan in Canadian families (Rioux et al., 2001). 
Two pediatric studies reported in white populations confirmed an association of the 
SLC22A variants with CD (Babusukumar et al., 2006; Russell et al., 2006). Studies have also 
demonstrated IBD5 epitasis with NOD2/CARD15 for both CD and UC (Giallourakis et al., 
2003; McGovern et al., 2003). First GWAS WTCCC 2007, confirmed the association of this 
locus with CD, followed by Raelson et al., 2007, Hampe et al., 2007, Franke et al., 2007. 
Furthermore, a meta-analysis by Barrett et al., 2008 pointed out another SNP, rs2188962, as 
the strongest disease-associated variant within IBD5. Besides CD, the TC haplotype has also 
been suggested to confer risk for UC (Waller et al., 2006; Palmieri et al., 2006). Preliminary 
data have also implicated this region associated to type I diabetes (Santiago et al., 2006). 
Although many studies have associated the region of chromosome 5, which contains 
SLC22A4 and SLC22A5 with CD, some investigators are hesitant to identify the mutations 
in these genes as causative of CD because of the tight linkage disequilibrium that exists 
between multiple genes in this chromosomal region. Hradsky et al., 2010 study on IBD5 
confirmed the association of the IBD5 risk haplotype and showed prominent role of the 
rs6596075 and IGR2063b_1 in the Czech population. Franke et al., 2010 meta-analysis further 
confirmed the association with CD. 
IL12B (5q33) 
IL12B encodes the p40 subunit of the heterodimeric cytokines interleukin IL12 and IL23 
(Langrish et al., 2004) produced by monocytes and dendritic cells. Association with CD was 
previously reported (WTCCC 2007) but not confirmed. The key role of the IL12/IL23 
pathway in chronic intestinal inflammation is supported by the association between IL23R 
and CD3 and strong functional evidence from mouse models of colitis (Uhlig et al., 2006;  
Yen et al., 2006). Later polymorphisms at IL12B have been associated with both CD (Parkes 
et al., 2007; Barrett et al., 2008; McGovern et al., 2010) and UC in several GWAS (Franke et 
al., 2008; Fisher et al., 2008). Anderson et al., 2011 meta-analysis further confirmed the 
association with CD and UC. This gene also has been implicated in T1D susceptibility with 
inconsistent results (Howson et al., 2009). Recently, Ferguson et al., 2010 reported 
differential effect of two IL12B (rs1363670 and rs6887695) variants in New Zealand 
population (carrying the rs1363670 C variant increased CD risk while carrying the rs6887695 
C variant decreased CD risk). Recent meta-analysies by Anderson et al., 2011 & Umeno et 
al., 2011 further confirmed the association of JAK2 with both UC and CD. 
PRDM1 (6q21) 
PRDM1 encodes for PR domain containing 1, with ZNF domain (also known as BLIMP1) 
protein known to play important roles in the proliferation, survival and differentiation of B 
and T lymphocytes. BLIMP-1 acts as master transcriptional regulator of plasma cells and 
repressor of beta-interferon (ǃ-IFN) gene expression. Anderson et al., 2011 meta-analysis 
first reported and Umeno et al., 2011 meta-analysis further confirmed the association of 
PRDM1 with ulcerative colitis and Crohn’s disease.  
CDKAL1 (6p22) 
CDKAL1 gene encodes CDK5 regulatory subunit associated protein 1-like 1 with unknown 
function which belongs to methyl-thiotransferase family. Variants in the intronic block of 
CDKAL1 have been associated with Crohn’s disease (Barrett et al., 2008 GWAS) and T2D 
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(Zeggini et al., 2008). CDKAL1 shows inconsistent replication in ulcerative colitis 
(McGovern et al., 2010 GWAS and Anderson et al., 2008 GWAS), this gene is also associated 
with psoriasis but does not exhibit genome-wide significance (Quaranta et al., 2009). 
JAK2 (9p24) 
Janus kinase 2 (JAK2) is another common member of the IL23 pathway genes conferring 
susceptibility to IBD. Barrett et al., 2008 meta-analysis of GWAS first reported the 
association of polymorphism in the JAK2 promoter region with CD. Later, several studies 
reported association with UC (Fisher et al., 2008; Franke et al., 2008; Asano et al., 2009; 
Festen et al., 2009). McGovern et al., 2010 confirmed strong association of SNP rs10974944 
in the JAK2 locus with UC in Dutch opulation. Franke et al., 2010 meta-analysis confirmed 
association with CD. Recent meta-analysis by Anderson et al., 2011 & Umeno et al., 2011 
further confirmed the association of JAK2 with both UC and CD. JAK2 gene locus is 
currently the subject of detailed re-sequencing efforts and functional studies to identify 
the causal variants. 
TNFSF15 (9q32) 
TNFSF15 (tumor necrosis factor ligand superfamily, member 15) was identified as the first 
CD-susceptibility gene through a genome-wide association screening of 72738 SNPs in 
Japanese population (Yamazaki et al., 2005). The association has been well replicated by 
several studies; study in a Korean cohort (Yang et al., 2008), an independent Japanese cohort 
(Kakuta et al., 2006) and a US cohort (Picornell et al., 2007) and meta-analyses of GWAS in 
European populations (Barrett et al., 2008) although the association was less significant in 
Europeans than in Japanese or Korean individuals. Yang et al., 2008 replicated findings from 
studies on Caucasian populations and established TNFSF15 as CD susceptibility genes on 
Korean patients. However, the reports of TNFSF15 association with UC in Caucasians have 
been inconsistent (Franke et al., 2008; Wang et al., 2010; Haritunians et al., 2010). In contrast 
to his own previous finding, Yang et al., 2011 reported no association between TNFSF15 and 
IL23R with UC in Koreans. However, TNFSF15 showed a marginal association with UC in 
male patients only. 
CARD9 (9q34) 
CARD9 gene located on 9q34.3 encodes caspase recruitment domain family, member 9 
protein, an adaptor molecule of PRR signaling. CARD9 is essential in the process of 
stimulating the innate immune signaling by intracellular and extracellular pathogens thus is 
an attractive candidate gene for IBD association (Underhill & Shimada, 2007). Zhernakova et 
al., 2008 performed a comprehensive analysis of candidate genes from 85 genes in the 
innate-immunity molecular pathway, in a group of 1851 IBD patients and 1936 controls, and 
observed association of the CARD9 variant, located in extended haploblock on 9q34.3, 
predominantly with UC and confirmed replication in the WTCCC GWAS data set. Later 
Barrett et al., 2009 GWAS study of UC confirmed CARD9 susceptibility. In 2010 McGovern 
et al., reported epistasis between CARD9 and Rel in Ulcerative colitis. Franke et al., 2010 also 
confirmed the association of CARD9 in UC and IBD.  
CREM (10p11) 
The cyclic adenosine 5'-monophosphate responsive element modulator (CREM) protein in 
humans encoded by the CREM gene binds to the IL2 gene promoter and suppresses 
expression of this cytokine (Tenbrock et al., 2002), critical for the initiation and termination 
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of the immune response and T cell development. Meta-analysis studies by McGovern et al., 
2010 confirmed the association of CREM with UC. Anderson et al., 2011 meta-analysis 
reported association with UC and CD. Recent meta-analysis study by Umeno et al., 2011 
confirmed the association of CREM with UC. 
CCNY (10p11) 
Cyclin Y (CCNY) belongs to family of highly conserved proteins that activate cyclin-
dependent kinases (Cdks) to regulate the cell cycle, transcription, and other cellular 
processes. Cyclin Y has not been characterized in any model organism. Very less is known 
for the human ortholog, CCNY. Franke et al., 2008 GWAS first reported association of 
SNP located in an intron of CCNY with the two IBD sub-phenotypes, CD and UC. 
Weersma et al., 2009 confirmed the association of CCNY as CD susceptibility loci in 
Dutch-Belgian cohort; though it is not yet clear whether CCNY plays a direct role in these 
diseases. Later the association of CCNY with UC and CD was confirmed in independent 
GWAS (Wang et al., 2010 and Waterman et al., 2010) and meta-analysis study by Umeno 
et al., 2011. First mutant allele reported for a Y-type cyclin, a null for Drosophila CycY 
generated by Liu & Finley, 2010 will provide further insight for the role of this conserved 
protein in human diseases. 
ZNF365 (10q21) 
Rioux et al., 2007 reported the first CD association with rs224136, a SNP 40kb downstream 
from Zinc finger 365 (ZNF365). GWAS performed in populations of Northern European 
descent by WTCCC, 2007 and Barett et al., 2008 GWAS further confirmed the CD 
susceptibility. Torkvist et al., 2010 reported ZNF365 in analysis of 39 CD risk loci in Swedish 
inflammatory bowel disease patients. Amre et al., 2010 reported ZNF365 as susceptibility 
loci for CD in Canadian children.  ZNF365 exists as four known transcript variants with 
variable expression across the species (ZNF365 isoforms A-D; GenBank NM_014951, 
NM_199450, NM_199451 and NM_199452). Of interest, studies in human colorectal cell lines 
showing interaction with histone acetyltransferase p300 during butyrate activation of the 
cyclin-dependent kinase inhibitor, p21waf1, a protein with increased levels in colonic crypts 
of patients with ulcerative colitis (Hofseth et al., 2003) and mice demonstrating dextran 
sulfate sodium-induced colitis homozygous for ZNF148-delN, highlight role for ZNF148 in 
gastrointestinal homoeostasis (Law et al., 2006). Haritunians et al., 2011 reported association 
of variant in ZNF365 isoform-D with CD. This study also demonstrated expression of 
ZNF365D in intestinal resections from both CD subjects and controls, markedly reduced 
expression levels of ZNF365D in EpsteineBarr virus-transformed lymphoblastoid cell lines 
from CD subjects homozygous for the risk allele (Ala), association of ZNF365D rs7076156 
genotype and altered expression of ZNF148 (transcription factor) known to be involved in 
gut homeostatsis. Umeno et al., 2011, meta- analysis study further confirmed the association 
of ZNF365 as common susceptibility loci for Chron’s disease and ulcerative colitis.   
NKX2-3 (10q24) 
NK2 transcription factor related, locus 3 (NKX2-3) is a member of the NKX family of 
homeodomain-containing transcription factors encoded by NKX2-3 gene is implicated in 
many aspects of cell type specification and maintenance of differentiated tissue functions. 
The rs10883365 variant of NKX2-3 gene on chromosome 10q24.2 was first identified as a CD 
susceptibility gene in the WTCCC 2007 GWAS in Caucasian patients. Parkes et al., 2007 
reported association of SNP rs10883365 (Pcomb=3.7 × 10
−10), within the NKX2-3 gene loci 
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contributing to CD. In addition, Fisher et al., 2008 reported a modest association (P = 3.3 × 
10-4 in the UC panel and P = 2.4 × 10-6 using the expanded WTCCC control panel) between 
rs10883365 and UC in a non-synonymous SNP scan. Franke et al., 2008 GWAS reported 
NKX2-3 previously unknown disease loci for UC from studies of CD. Further confirmed 
association between CD and UC came from Barrett et al., 2008 and Franke et al., 2010 
GWAS. Replication studies from Netherlands (Weersma et al., 2009) and Japan (Yamazaki et 
al., 2009) further confirmed the association with CD. Dutch study demonstrated that the 
association between the rs10883365 variant of NKX2-3 and CD was linked to smoking 
status, with the risk being more pronounced in active and passive smokers (Van der Heide 
et al., 2010). Recently, Meggyesi et al., 2010 confirmed that rs10883365 variant was 
associated with UC and CD susceptibility in the allelic and genotypic models with an OR of 
1.53 and 1.24 respectively in Eastern European patients.  
LRRK2–MUC19 (12q12) 
Leucine-rich repeat kinase 2 (LRRK2), also known as dardarin, member of leucine-rich 
repeat kinase family is an enzyme, in humans is encoded by LRRK2 gene. The protein is 
mainly expressed in the cytoplasm of neurons, myeloid cells and monocytes and is thought 
to be involved in the process of autophagy. LRRK2 was initially identified as the defective 
gene at PARK8 susceptibilty locus responsible for autosomal Parkinson’s disease (PD). The 
meta-analysis of GWAS by Barrett et al., 2008 identified LRRK2-MUC19 as CD susceptibility 
loci. Franke et al., 2010 GWAS further confirmed the association with CD. However, Phillips 
et al., 2010 haplotype-tagging study of germline variation of MUC19 in inflammatory bowel 
disease suggested that LRRK2 represents the susceptibility gene at this region. Recently, 
meta-analysis of published studies by Umeno et al., 2011, reported LRR2-MUC19 as 
common susceptibility loci for CD and UC. With no known physiological substrate the role 
of LRRK2 in cellular context remains poorly understood. Zhang et al., 2009, GWAS reported 
association of an SNP located upstream from the LRRK2 locus with a higher susceptibility to 
Mycobacterium leprae. The study also highlighted other genes already known to be 
associated with CD, such as NOD2, TNFS15, and C13ORF31, suggesting that the pathways 
involved in the control of M. leprae might be also involved in the susceptibility to CD. 
Gardet et al., 2010 reported that LRRK2 is an IFN- target gene with increased expression in 
intestinal tissues upon CD inflammation, suggesting involvement in signaling pathways 
relevant to CD. Another member, MUC19, along-with LRRK2 is an important player in the 
rapidly evolving story of IBD. MUC19 encodes a mucin involved in epithelial cell lining 
protection (Hollingsworth & Swanson, 2004). Of interest, Mucin proteins protect the intestinal 
epithelium from injury are further supported by the fact that mucin deficiency leads to 
intestinal inflammation in mouse models of colitis (Van der Sluis et al., 2006). Meta-analysis by 
Umeno et al., 2011 reported LRRK2-MUC19 as novel susceptibility loci for CD and UC. 
C13orf31 (13q14) 
C13orf31 gene encoding chromosome 13 open reading frame 31 was first associated with 
leprosy in GWAS (Zhang et al., 2009). Meta-analysis by Anderson et al., 2011 reported 
C13orf31 as newly confirmed UC risk loci. Meta-analysis by Umeno et al., 2011 reported it as 
common susceptibility loci for both CD and UC. 
STAT3 (17q21)  
STAT3 codes for a transcription factor that is involved in multiple pathways and functions, 
including Jak-STAT pathway, neuron axonal guidance, apoptosis, activation of immune 
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responses, and Th17 cell differentiation (Egwuagu, 2009). SNP (rs744166) within the STAT3 
gene was associated to MS.  Interestingly, the A allele of rs744166 tagging the MS-protective 
haplotype is associated with Crohn disease (Barrett et al., 2008 GWAS) and mutations in 
STAT3 are known to cause hyperimmunoglobulin E recurrent infection syndrome (HIES) 
(Holland et al., 2007), a rare autosomal-dominant disorder characterized by elevated 
immunoglobulin E levels and inflammation implying that STAT3 represents a shared risk 
locus for at least two autoimmune diseases. STAT3 was reported as T1D susceptibility locus 
by Fung et al., 2009, but it was not confirmed by other GWAS and meta-analysis studies. 
Recent meta-analyses by Anderson et al., 2011 and Umeno et al., 2011 confirmed the 
association with UC and CD. 
SBNO2 (19p13) 
Strawberry notch homologue 2 (SBNO2) gene located on chromosome 19 encodes for large 
170-kDa proteins containing canonical DExD/H helicase domains. SBNO2 is key component 
of the IL-10 mediated anti-inflammatory pathway (Kasmi et al., 2007). Recent meta-analysis 
by Umeno et al., 2011 identified SBNO2 as novel common susceptibility loci for CD and UC. 
TNFRSF6B, STMN3, RTEL1, ARFRP1, ZGPAT, SLC2A4RG, ZBTB46 (20q13) 
The 20q13 signal resides in a complex telomeric region of LD and harbors the genes for 
STMN3 (stathmin-like 3), RTEL1 (regulator of telomere elongation helicase 1), TNFRSF6B 
(tumor necrosis factor receptor superfamily member 6B), ARFRP1 (ADP-ribosylation factor 
related protein 1), ZGPAT (zinc finger CCCH-type with G patch domain), LIME1 (Lck 
interacting transmembrane adaptor 1), SLC2A4RG (solute carrier family 2 member 4 
regulator) and ZBTB46 (zinc finger and BTB domain containing 46). These loci contribute to 
both CD and UC susceptibility. The protein product for TNFRSF6B acts as a decoy receptor 
(DCR3) in preventing FasL-induced cell death, and a resistance to FasL-dependent 
apoptosis. Kugathasan et al., 2008 GWAS in a cohort of 1011 individuals using stratification 
of IBD by age of onset and 4250 matched controls identified previously unreported 
susceptibility loci for pediatric-onset IBD at 20q13 and 21q22. On the basis of the differences 
in serum DCR3 concentration between individuals with IBD with and without the identified 
SNPs, and its known biologic function, this study highlights TNFRSF6B as the most 
plausible candidate within the 20q13 locus.  
ICOSLG (21q22) 
Inducible costimulator-ligand (ICOS-L) is a member of the B7 family of costimulatory 
ligands (Coyle & Gutierrez-Ramos, 2001), shares 19–20% sequence identity with CD80 and 
CD86. ICOS-L binds to ICOS, a T cell-specific costimulatory molecule homologous to CD28 
and CTLA-4. ICOSLG is intimately involved in proliferation and differentiation of T 
lymphocytes (Ito et al., 2007). Barrett et al., 2008 GWAS study first confirmed the association 
of ICOSLG with CD. The locus on chromosome 21q22 harboring genes including inducible 
T cell costimulator (ICOSLG) along-with autoimmune regulator (AIRE) and periodic 
tryptophan protein 2 homologue (PWP2) has been shown to influence susceptibility to both 
adult and pediatric CD and ulcerative colitis (UC). Imielinski et al., 2009 reported ICOSLG 
among the common variants at five new loci associated with early-onset inflammatory 
bowel disease. Franke et al., 2010 meta-analysis study further confirmed association with 
CD. Coquerelle et al., 2009 demonstrated that the treatment of trinitrobenzene sulfonic acid-
induced murine colitis was ameliorated by anti-CTLA-4 antibodies through the induction of 
ICOShigh T regulatory cells. Sato et al., 2004 demonstrated high expression of ICOS in 
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activated CD4+ LPMC of IBD patients contributing to the dysregulated immune responses 
in IBD suggesting a role for the ICOS-ICOSLG interaction in CD pathogenesis. Henderson et 
al., 2011 using a genome wide haplotype tagging approach in first family-based association 
analysis strategy reported that variation in ICOSLG influences CD susceptibility and 
demonstrated that the signal at the 21q22 locus is most likely to be due to germline variation 
at the 3 end begging for deep sequencing of the 3’UTR of the gene to identify causative 
variants.   
3. Conclusions 
This chapter gives an overview of comparative genetic analyses for type 1 diabetes and 
inflammatory bowel disease. Genome wide association studies have revolutionized the field 
of complex disease genetics. For the first time there is real consensus on the role of specific 
genetic factors underpinning common disorders. However, such genome wide scans can 
lack coverage in certain regions where it is difficult to genotype so it is possible that other 
loci with reasonable effect sizes remain to be uncovered.  
It is clear that larger sample sizes and bigger meta-analyses of GWAS datasets will lead to 
the uncovering of further loci, albeit with lower and lower effect sizes. However it has been 
predicted that there are a myriad of rare variants (possibly with larger effects) contributing 
to disease that cannot be detected on current genotyping platforms. To uncover the 
remaining “missing heritability” in complex diseases like T1D and IBD (Manolio et al., 
2009), investigators in the near future will need to work on large, high-throughput 
sequencing efforts involving thousands of DNA samples from affected subjects and a 
similar number of controls.  
Novel genomic techniques, such as Next-Generation DNA Sequencing (NGS), have opened 
new avenues in the elucidation of genetic defects and had speeded up the identification of 
causative gene variants to systematically tackle previously intractable genetic disorders 
which would be missed by GWAS. NGS involves the use of three specific techniques: DNA 
capture of specific regions (usually GWAS guided) usually in the 1-10 megabase range; 
exomic sequencing (the sequence of all coding regions of the genome), with capture of about 
50 megabases; and the sequencing of entire human genome (~3 billion base pairs), in 
affected and unaffected individuals. Recent studies have used this approach to identify 
mutations for Miller syndrome (Roach et al., 2010) and Charcot-Marie-Tooth disease (Lupski 
et al., 2010). Although powerful, NGS is still very expensive and time consuming. However 
in future, with drop in costs of whole genome sequencing, it will likely become the 
dominant method for identifying mutations.  
Recent GWAS have showed cross-talk of genes and autoimmune diseases. We report 16 
common loci between T1D and IBD, six with opposite effects. As predicted, the role of some 
of the overlapping genes is not always the same for T1D, UC and CD. Thus, to discover all 
common, opposing and different variants for autoimmune disorders sequencing is 
necessary.  
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